An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) has launched a public offering of $100 million in common stock, which includes pre-funded warrants for select investors. The underwriters may purchase an additional $15 million of shares within 30 days. The offering is subject to market conditions, with no guarantee of completion or specific terms. This follows their earlier filed shelf registration statement with the SEC. Morgan Stanley, SVB Securities, and Cowen are managing the offering.
Positive
Planned public offering aims to raise $100 million, providing necessary funds for growth and development.
Potential for an additional $15 million in shares through underwriter option, increasing capital influx.
Negative
Public offering may lead to shareholder dilution.
Uncertainty regarding market conditions could affect the offering's completion and terms.
SEATTLE--(BUSINESS WIRE)--
Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock and, in lieu of shares of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, pursuant to its existing shelf registration statement. It is expected that the underwriters of the offering will be granted an option for a period of 30 days to purchase up to an additional $15.0 million of shares of common stock at the public offering price, less the underwriting discounts and commissions. All shares of common stock to be sold in the proposed offering will be sold by Alpine. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Morgan Stanley, SVB Securities and Cowen are acting as joint book-running managers for the proposed offering. Wedbush PacGrow is acting as lead manager for the proposed offering.
A shelf registration statement relating to the securities offered in the proposed public offering described above was filed with the Securities and Exchange Commission (SEC) on May 14, 2021 and declared effective by the SEC on May 20, 2021. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by telephone: 1-866-718-1649, or by email at prospectus@morganstanley.com; SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@svbsecurities.com; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding the anticipated public offering. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to, uncertainties related to market conditions and the completion of the proposed public offering on the anticipated terms or at all, as well as the other risks identified in our filings with the SEC. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.
What is Alpine Immune Sciences' public offering amount and details?
Alpine Immune Sciences announced a public offering of $100 million in common stock and pre-funded warrants, with an option for underwriters to purchase an additional $15 million.
Who are the underwriters for ALPN's public offering?
Morgan Stanley, SVB Securities, and Cowen are acting as joint book-running managers for the public offering.
When was the shelf registration statement for ALPN filed?
The shelf registration statement was filed with the SEC on May 14, 2021, and declared effective on May 20, 2021.
What are the risks associated with Alpine Immune Sciences' public offering?
The offering is subject to market conditions and may not be completed or may change in terms, creating uncertainty for investors.
How could the public offering affect existing shareholders of ALPN?
The public offering could result in shareholder dilution, impacting existing shareholders' ownership percentages.
